CICC: Maintains Far East Pharmaceutical (00512.HK) as "outperform industry" rating and raises target price to HKD 9.6.

Wisdom Finance APP learned that CICC released a research report stating that it maintains a forecast of 0.6/0.63 Hong Kong dollars for Far East Pharmaceutical's (00512.HK) 2025/2026 EPS. The current stock price corresponds to a 13.9 times/13.2 times price-to-earnings ratio for 2025/2026. The bank maintains an "outperform" rating, considering the company's RDC pipeline is close to fruition, raising the target price by 20.0% to 9.6 Hong Kong dollars, corresponding to a 16.0 times/15.2 times price-to-earnings ratio for 2025/2026, with an upside potential of 15.4% compared to the current stock price.